- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03841396
A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.
A Phase IV, Randomised, Double-blind Study Comparing the Local Tolerability of Two Subcutaneous Heparins, Fraxiparine and Clexane, in Healthy Volunteers.
Study Overview
Detailed Description
This was a Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of pain following a single dose subcutaneous administration of two LMWHs respectively. This study included an approximate seven-day screening period (screening visit to day 0), followed by three visits (Visit 2, 3 and 4) in one-week intervals, in which each participant should have received a single sequence of subcutaneous injections of Placebo, Fraxiparine and Clexane, in a randomised order, on the three separate occasions. This was then followed by a safety follow-up visit, one week after the administration of the last dose of the study product.
Fifteen (N = 15) healthy, consenting participants, fulfilling the inclusion criteria, were randomised to take part in this study. All participants received a single sequence of subcutaneous injections, on separate occasions at one week intervals, over the duration of the treatment phase of the study. Fifteen (N=15) participants received Fraxiparine, fifteen (N=15) participants received Clexane and fifteen (N=15) participants received Placebo. Two participants were screened however did not meet the eligibility criteria and therefore were not included into the study. Informed consent was obtained at Screening Visit 1 (day -7 to 0) before any trial-related procedures were be performed. Visual analogue and 11-point numeric rating scales were utilised to measure pain intensity after a single injection of investigational product. These scales were also used to assess burning and pruritus. All scales were be completed at set time intervals over a 30 minute period, i.e. 1, 3, 5, 10, 15 and 30 minutes after the injections were completed. Hematoma, erythema and oedema were measured minutes and 1, 2 and 3 days after the injection, using transparent millimetric measuring paper. Safety bloods were drawn at each visit.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female participant.
- Aged 18 years to 55 years.
- Medically healthy participants.
- Weight Females: ≥ 45 kg; Males ≥ 57 kg.
- Body Mass Index (BMI) of 18,5 to 29,9 kg/m2.
- Female participants of child-bearing potential must have a negative urine pregnancy test at screening and be willing to use effective contraceptives throughout the trial duration.
- Participants must be able to understand and follow the instructions of the Investigator, understand and give informed consent, and be willing, committed, and able to return for all site visits and complete all study-related procedures.
Exclusion Criteria:
- A known hypersensitivity to Clexane or Fraxiparine or any components thereof - especially allergies to latex, pork products, sulfites and benzyl alcohols.
- Female participants who are pregnant or lactating.
- Any coagulopathy - Anaemia, thrombocytopenia, hemophilia, haemorrhagic diathesis (Bleeding, Bruising, Clotting disorders).
- Active gastric or duodenal ulcer or history of previous gastric duodenal bleeding or gastrointestinal bleeding.
- Participants on the following medications: Anti-coagulants, Non-Steroidal Anti-inflammatory Drugs (NSAID)s, glycoprotein IIb/IIIa anticoagulants, thrombolytic agents, platelet-inhibitors, acetylsalicylic acid, sulfinpyrazone, quinine - containing remedies and/drinks, treprostinil, apixaban, drotecogin alfa, danshen, dong quai, evening primrose oil, gingko, policosanol and willow bark as well as hyperkalemia aggravators in the last 7 days.
- A Cerebrovascular incident (hemorrhagic or ischemic).
- Deep Vein Thrombosis and/ Pulmonary embolism.
- Acute infective endocarditis or history of acute endocarditis.
- Participants with Hypertension.
- Diabetics.
- Any injuries or surgery of the ears, eyes, brain or spinal cord within the last 18 months.
- Renal insufficiency (Creatinine and Urea not within normal ranges).
- Hepatic Insufficiency ( aspartate aminotransferase (AST) and alanine transaminase (ALT) within normal ranges).
- Participants with Heamorrhagic Retinopathy.
- Participants with prosthetic heart valve/s.
- Participants currently receiving any other treatments administered via subcutaneous or intramuscular routes.
- Participants with a history or current endocrine, pulmonary, cardiovascular, gastrointestinal, neurological, immunological, renal, hepatic, dermatologic, haematologic, psychiatric disease other than specified that might have/cause unwanted effects/outcomes in this clinical trial.
- Alcohol and/ or drug abuse in the past year.
- In the opinion of the investigator, the participant is not reliable to participate in the trial.
Participants that have taken part in a clinical trial involving Clexane and/ Fraxiparine.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Fraxiparine
Nadroparine, Pre-filled syringe, 3800IU, single dose
|
All participants received a single dose of sodium chloride as placebo
Other Names:
|
ACTIVE_COMPARATOR: Clexane
Enoxaparin, Pre-filled syringe, 40 mg, single dose
|
All participants received a single dose of sodium chloride as placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Visual Analog Scale (VAS) scores of pain intensity at injection site following a single subcutaneous injection of placebo, Fraxiparine or Clexane
Time Frame: Over a period of 30 minutes
|
Visual Analogue Scales for pain intensity was performed at different time points namely 1, 3, 5, 10, 15 and 30 minutes after administration of the investigational product (IP) at Visit 2, 3 and 4. Pain intensity: 0 mm - No pain; 100 mm - Worst pain
|
Over a period of 30 minutes
|
Comparison of Numeric Rating Scale (NRS) scores of pain intensity at injection site following a single subcutaneous injection of placebo, Fraxiparine or Clexane.
Time Frame: Over a period of 30 minutes
|
11-point NRS for pain intensity was performed at different time points namely 1, 3, 5, 10, 15 and 30 minutes after administration of the investigational product (IP) at Visit 2, 3 and 4. Pain intensity: 0 - No pain; 10 - Worst pain
|
Over a period of 30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification of local injection site reaction
Time Frame: 10 and 30 minutes and 1, 2 and 3 days after the injection.
|
Hematoma, erythema and oedema were measured 10 and 30 minutes and 1, 2 and 3 days after the injection, using transparent millimetric measuring paper.
|
10 and 30 minutes and 1, 2 and 3 days after the injection.
|
Pain duration
Time Frame: 1, 3, 5, 10, 15 and 30 minutes after administration of IP.
|
Duration of pain at injection site.
|
1, 3, 5, 10, 15 and 30 minutes after administration of IP.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSA-15-ASP-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Injection Site Reaction
-
Jeffrey Alan Klein, MDNot yet recruitingAnesthesia, Local | Injection Site Irritation | Injection Site Discomfort | Injection Site Bruising | Benzoic Acid Adverse ReactionUnited States
-
Ain Shams UniversityCompletedPropofol Adverse Reaction | Injection Site ColdnessEgypt
-
Eitan MedicalThomas Jefferson UniversityRecruitingInjection Site Irritation | Injection Site Reaction | Injection SiteUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedInjection; Complications, Sepsis | Injection Site Disorder | Injection Site Extravasation | Intentional Poisoning by SiliconeFrance
-
Hospital M'Boi MirimCompletedKnowledge, Attitudes, Practice | Injection Site ReactionsBrazil
-
Mahidol UniversityCompletedInjection Reactions Site | Systemic ReactionsThailand
-
Erevna Innovations Inc.Completed
-
Merz North America, Inc.RecruitingInjection Site ReactionSpain
-
Chang Gung Memorial HospitalRecruiting
-
Istanbul Saglik Bilimleri UniversityCompletedInjection Site Reaction | Injection Site Bruising
Clinical Trials on Sodium chloride
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular DiseasesUnited Kingdom
-
University of JenaCompletedCystic Fibrosis | RhinosinusitisGermany
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted
-
Federal University of São PauloCompleted
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
Austin HealthCompletedSystemic Inflammatory Response Syndrome | Renal Impairment | OliguriaAustralia
-
Medical University of GrazCompleted
-
Osaka General Medical CenterCompletedEmergent Coronary ProcedureJapan
-
Lars Wiuff AndersenUniversity of AarhusRecruiting